NYSEIndustrialsInformation Technology ServicesSnapshot 2026-07-07
Reading BR? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track BR free→Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Industrials is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue is growing steadily — about 8% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 17%.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 1% on a typical day and fell roughly 49% in its worst 12-month stretch.
View RiskBroadridge Financial Solutions (BR) aims to grow recurring revenue through strategic partnerships. Revenue grew 8% year over year, and the last quarter beat expectations. It trades at 15× P/E, below the peer median of 32×. This suggests that the price reflects less growth than expected. A specific risk is the potential for a credibility hit if guidance is cut. Peer multiples imply a price about 26% above where it trades; this read is provisional.
Trailing returns as of 2026-07-06. BR is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 9 analysts currently covering BR (as of Jul 2026).
Based on 4 Wall Street analysts offering 12-month price targets for BR in the last 4 months.
A consensus fair price across 14 valuation methods, at three horizons. Current price $144.77. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Industrials (broad) — fair value, gap to price, and forward P/E.
Advances: Increase Recurring Revenue Growth
Partnership enhances recurring revenue growth potential.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-06. EPS is implied from price ÷ P/E. Not investment advice.
Current $144.77
The last 12 months of price, then the range of analyst 12-month targets from today’s $144.77.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Increase Recurring Revenue Growth
Increased transaction volume supports recurring revenue growth.
New board member enhances regulatory oversight.
New board member enhances regulatory oversight capabilities.
Partnership with Kyndryl enhances product offerings.
Advances: Increase Recurring Revenue Growth
Significant stock rise indicates strong market confidence.
